Industry

Training for conceptual competence in psychiatry provides a new way forward to address theoretical and philosophical issues in mental health research and practice.

Researcher criticizes the many ways opposing viewpoints and dissenting voices are squashed in the field of medicine.

The results of five large-scale clinical trials of antidepressants have never been made accessible to the public, a data set compiled by an international team of researchers shows. Their discovery highlights the incompleteness of available data on the safety and efficacy of antidepressant drugs.

Researchers suggest that the pharmaceutical industry had a vested interest in using the term “discontinuation” in order to hide the severity of physical dependence and withdrawal reactions many people experience from antidepressants.

A new analysis, published in Lancet Neurology, demonstrates how Biogen is spinning results from two failed trials for a new Alzheimer's drug.

An issue of Lancet Psychiatry is devoted to clarifying the lack of efficacy for Zoloft (sertraline).

Experts across the globe point to the harms of drug companies’ influence on research, practice, and education in healthcare noting that it compromises patient care.

Researchers critically examine the underlying assumptions and implications of a new WHO mental health technology designed to streamline psychiatric assessment internationally.

Current standards for clinical trials rely on statistical methods that allow for ineffective treatments to gain approval.

A closer look at a new study reporting that the supplement D-cycloserine improved anxiety when used with exposure therapy.

When it comes to ADHD, some researchers suggest that medical textbooks provide inaccurate and misleading information.

A new review, published in BMJ Evidence-Based Medicine, concludes that antidepressants should not be used as the risks outweigh evidence for benefits.

Despite their finding, the researchers suggest that SSRIs be given to people who do not meet criteria for depression or anxiety.

The approval of the digital antipsychotic may open the door for more pharmaceutical company profits without evidence of benefits to patients.

MIA's Gavin Crowell-Williamson interviews PharmedOut founder Dr. Adriane Fugh-Berman about Big Pharma's influence on medical education.

Ethnographic research sheds light on extensive psychopharmaceutical use by soldiers in post 9/11 U.S. wars.

Research illustrates privacy concerns with how mental health applications collect and share users’ data.

Akansha Vaswani interviews Dr. John Read about the influences on his work and his research on madness, psychosis, and the mental health industry.

Industry-funded continuing medical education (CME) influences physicians to prescribe more opioids, focus less on the consequences.

A new study casts doubt on whether such biotypes for depression exist.

New study finds that antidepressants may negatively impact recovery after psychiatric hospitalization.

Could the statistical phenomenon of regression to the mean be responsible for the dramatic effects of placebo—as well as the supposed effectiveness of some psychiatric drugs?

Interviews with psychosocially oriented psychologists demonstrate their experiences of discomfort with the hegemony of the medical model in their place of work and the conflicts that arise when they attempt to provide alternatives.

Researchers examine how rapid discontinuation can mimic the relapse of mental health symptoms and confound psychiatric drug studies.

Neuroscience researchers find no differences in brain connectivity between children with diagnoses of autism, ADHD, and those with no diagnoses.